An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors in Pediatric Participants
Latest Information Update: 27 Mar 2025
At a glance
- Drugs Ponatinib (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Leukaemia; Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Incyte Biosciences International
- 13 Aug 2024 Planned End Date changed from 4 Jan 2025 to 30 Jan 2026.
- 13 Aug 2024 Planned primary completion date changed from 7 Dec 2024 to 30 Jan 2026.
- 12 Sep 2023 Planned number of patients changed from 60 to 85.